Sigma-Aldrich, CrystalGenomics collaborate for API development

Gilles Cottier, President, SAFC.

ST LOUIS, US: The custom manufacturing and services business unit of Sigma-Aldrich Corporation, SAFC, has signed an agreement with Seoul, South Korea-based CrystalGenomics to support the development of active pharmaceutical ingredients (APIs) for next-generation non-steroidal anti-inflammatory drugs (NSAID). The agreement represents SAFC’s premier pre-formulation services contract into the growing South Korean pharmaceutical market.

CrystalGenomics will employ SAFC’s pharmorphix pre-formulation technology services which are based in Cambridge, UK, to enable understandings of the physical properties of APIs. The services can also aid in determining the selection of optimal crystallization processes, ensure batch-to-batch consistency in manufacturing and help to maintain efficacy and patient safety.

“Our expertise in the pre-formulation of pharmaceuticals has allowed us to engage with CrystalGenomics through this agreement and to introduce our unique technologies to the South Korea market. As the drug discovery and development process becomes increasingly complex and expensive, we feel that our pre-formulation services are well-positioned to help pharmaceutical and biopharmaceutical companies around the globe to accelerate their pipelines,” said Gilles Cottier, President, SAFC.

© WOC News